Breaking News Instant updates and real-time market news.

ALKS

Alkermes

$59.29

4.6 (8.41%)

, NKTR

Nektar

$84.00

8.34 (11.02%)

07:43
02/15/18
02/15
07:43
02/15/18
07:43

Alkermes shares benefited from focus on NKTR-214, says Jefferies

Despite slowing Vivitrol sales, Alkermes (ALKS) shares rallied following yesterday's Q4 report from the recent focus on Nektar Therapeutics' (NKTR) IL-2 inhibitor NKTR-214, Jefferies analyst Biren Amin tells investors in a research note. Alkermes' early stage immuno-oncology candidate ALKS 4230 is designed for selective IL-2 receptor activation to enhance tumor killing, the analyst adds. He notes ALKS 4230 is under test for intravenous administration in dose escalation stage with four-to-seven cohorts and will initiate dose expansion cohort by the end of 2018. Amin sees "multiple milestones" for Alkermes in 2018 and keeps a Buy rating on the shares with a $66 price target.

ALKS

Alkermes

$59.29

4.6 (8.41%)

NKTR

Nektar

$84.00

8.34 (11.02%)

  • 26

    Feb

  • 04

    Apr

  • 03

    May

ALKS Alkermes
$59.29

4.6 (8.41%)

11/28/17
FBCO
11/28/17
NO CHANGE
Target $66
FBCO
Outperform
Alkermes agreement with Biogen should help monetize ALKS 8700, says Credit Suisse
Credit Suisse analyst Vamil Divan views Alkermes (ALKS) ALKS 8700 agreement with Biogen (BIIB) as a positive financial move for an underappreciated pipeline asset. The analyst notes that ALKS 8700 has not been given much credit by investors to date due to limited clinical data and patent uncertainty. Divan reiterates an Outperform rating and $66 price target on Alkermes shares.
11/28/17
BERN
11/28/17
NO CHANGE
Target $318
BERN
Outperform
Biogen price target raised to $318 from $310 at Bernstein
Bernstein analyst Aaron Gal raised his price target for Biogen (BIIB) to $318 from $310 after the company announced a licensing agreement with Alkermes (ALKS) to develop and commercialize ALKS 8700, a modified fumarate with a potentially differentiated GI tolerability profile. The analyst views this important improvement in Biogen's position in MS given the risk of generic Tecfidera. Further, Gal thinks the Street may be underappreciating the value of the asset. He reiterates an Outperform rating on Biogen's shares.
12/14/17
JEFF
12/14/17
NO CHANGE
Target $66
JEFF
Buy
Jefferies received positive feedback on Vivitrol at psychiatry conference
Jefferies analyst Biren Amin says he received positive feedback on Alkermes' Vivitrol at the American Academy of Addiction Psychiatry conference. Key opinion leaders have a consensus view on Vivitrol of its comparable efficacy and safety versus Suboxone, Amin tells investors in a research note. Psychiatrists view the recently approved Sublocade as a meaningful alternative to reduce abusive use of oral Suboxone, but don't believe it as a major threat to Vivitrol as physician acceptance of Vivitrol largely depends on its unique antagonist mechanism, the analyst adds. He believes Alkermes is in a strategic position for "significant growth" of Vivitrol longer term, supported by physician advocacy, patient awareness and Trump administration's pledges to fight the opioid epidemic. Amin has a Buy rating on Alkermes with a $66 price target.
02/15/18
SBSH
02/15/18
NO CHANGE
Target $62
SBSH
Neutral
Alkermes catalysts are the major focus this year, says Citi
Citi analyst Liav Abraham says that while Alkermes' (ALKS) fiscal 2018 revenue outlook came in below expectations, catalysts are the "major force this year." The analyst expects data from two of the company's pivotal programs and clarity around the regulatory pathway for ALKS 5461. Further, the strategic value of ALKS 4230 "can also not be discounted," following the collaboration between Bristol-Myers (BMY) and Nektar Therapeutics (NKTR), Abraham tells investors in a post-earnings research note. ALKS 4230, an IL-2 inhibitor, gives Alkermes optionality as it is not an "obvious" fit into the company's psychiatry-oriented portfolio, the analyst contends. She keeps a Neutral rating on Alkermes with a $62 price target.
NKTR Nektar
$84.00

8.34 (11.02%)

02/05/18
JEFF
02/05/18
NO CHANGE
Target $88
JEFF
Buy
Bristol-Myers makes sense as potential Nektar acquirer, says Jefferies
Jefferies analyst David Steinberg believes Bloomberg's report that Nektar Therapeutics (NKTR) is exploring strategic options is not surprising. For many years Nektar's most important assets were out licensed, but that is no longer the case, Steinberg tells investors in a research note. The company's current partner Bristol-Myers Squibb (BMY) would make sense to be on the short list of potential acquirer, the analyst adds. Steinberg keeps a Buy rating on Nektar with an $88 price target.
02/14/18
MZHO
02/14/18
NO CHANGE
Target $89
MZHO
Buy
Nektar deal with Bristol-Myers could eventually lead to takeover, says Mizuho
After Nektar (NKTR) announced a new immune-oncology collaboration agreement with Bristol-Myers Squibb (BMY), Mizuho analyst Difei Yang said she believes the deal values Nektar at approximately $9B-$10B and may lead to an eventual takeout. She maintains her Buy rating and $89 price target on Nektar shares.
02/14/18
JEFF
02/14/18
NO CHANGE
Target $88
JEFF
Buy
Nektar takeover not off table with Bristol deal, says Jefferies
Jefferies analyst David Steinberg finds it important that Nektar Therapeutics (NKTR) retains ownership of NKTR-214 following its collaboration with Bristol-Myers (BMY) and that it can continue to collaborate with other companies. Further, the potential to be acquired is not off the table, Steinberg tells investors in a research note. The analyst keeps a Buy rating on Nektar with an $88 price target.

TODAY'S FREE FLY STORIES

WEI

Weidai

$10.00

-0.14 (-1.38%)

06:52
12/14/18
12/14
06:52
12/14/18
06:52
Initiation
Weidai initiated  »

Weidai initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TFX

Teleflex

$256.24

-2.055 (-0.80%)

06:51
12/14/18
12/14
06:51
12/14/18
06:51
Hot Stocks
NeoTract: 12-month results from study of UroLift System published »

NeoTract, a wholly owned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLY

Eli Lilly

$114.87

0.51 (0.45%)

06:51
12/14/18
12/14
06:51
12/14/18
06:51
Hot Stocks
Eli Lilly expands collaboration with Evidation Health for Andromeda platform »

Eli Lilly and Evidation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

SBUX

Starbucks

$66.90

0.8 (1.21%)

06:50
12/14/18
12/14
06:50
12/14/18
06:50
Recommendations
Starbucks analyst commentary  »

Starbucks price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

DEA

Easterly Government Properties

$17.41

0.03 (0.17%)

06:50
12/14/18
12/14
06:50
12/14/18
06:50
Upgrade
Easterly Government Properties rating change  »

Easterly Government…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$78.44

0.95 (1.23%)

06:47
12/14/18
12/14
06:47
12/14/18
06:47
Hot Stocks
Merck to acquire Antelliq Group for approximately EUR2.1B »

Merck and privately held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jan

  • 16

    Feb

SBUX

Starbucks

$66.90

0.8 (1.21%)

06:46
12/14/18
12/14
06:46
12/14/18
06:46
Recommendations
Starbucks analyst commentary  »

Starbucks' LT…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

MRK

Merck

$78.44

0.95 (1.23%)

06:45
12/14/18
12/14
06:45
12/14/18
06:45
Hot Stocks
Breaking Hot Stocks news story on Merck »

Merck to acquire Antelliq…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jan

  • 16

    Feb

LSCC

Lattice Semiconductor

$6.63

-0.05 (-0.75%)

06:45
12/14/18
12/14
06:45
12/14/18
06:45
Upgrade
Lattice Semiconductor rating change  »

Baird upgrades Lattice to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTI

TechnipFMC

$21.35

0.11 (0.52%)

06:44
12/14/18
12/14
06:44
12/14/18
06:44
Upgrade
TechnipFMC rating change  »

TechnipFMC upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$247.71

2.27 (0.92%)

06:43
12/14/18
12/14
06:43
12/14/18
06:43
Recommendations
Adobe analyst commentary  »

Adobe price target cut to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCL

Carnival

$56.60

0.09 (0.16%)

06:41
12/14/18
12/14
06:41
12/14/18
06:41
Recommendations
Carnival analyst commentary  »

Nomura sees 30% total…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 20

    Dec

DLTR

Dollar Tree

$85.04

0.45 (0.53%)

06:38
12/14/18
12/14
06:38
12/14/18
06:38
Upgrade
Dollar Tree rating change  »

Dollar Tree upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$247.71

2.27 (0.92%)

06:37
12/14/18
12/14
06:37
12/14/18
06:37
Recommendations
Adobe analyst commentary  »

Adobe price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTI

TechnipFMC

$21.35

0.11 (0.52%)

06:36
12/14/18
12/14
06:36
12/14/18
06:36
Upgrade
TechnipFMC rating change  »

TechnipFMC upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARE

Alexandria Real Estate

$123.00

1.88 (1.55%)

06:36
12/14/18
12/14
06:36
12/14/18
06:36
Upgrade
Alexandria Real Estate rating change  »

Alexandria Real Estate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

SU

Suncor

$30.67

-0.31 (-1.00%)

06:35
12/14/18
12/14
06:35
12/14/18
06:35
Hot Stocks
Suncor announces 2019 capital program of $4.9B-$5.6B »

Suncor released its 2019…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BECN

Beacon Roofing

$31.84

-0.22 (-0.69%)

06:35
12/14/18
12/14
06:35
12/14/18
06:35
Downgrade
Beacon Roofing rating change  »

Beacon Roofing downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADSK

Autodesk

$135.56

-2.25 (-1.63%)

, WDC

Western Digital

$39.95

-1.01 (-2.47%)

06:34
12/14/18
12/14
06:34
12/14/18
06:34
Hot Stocks
Autodesk adds Western Digital CEO Stephen Milligan to board »

Autodesk (ADSK) announced…

ADSK

Autodesk

$135.56

-2.25 (-1.63%)

WDC

Western Digital

$39.95

-1.01 (-2.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CIEN

Ciena

$34.90

2.765 (8.60%)

06:34
12/14/18
12/14
06:34
12/14/18
06:34
Recommendations
Ciena analyst commentary  »

Ciena price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CODX

Co-Diagnostics

$2.20

(0.00%)

06:32
12/14/18
12/14
06:32
12/14/18
06:32
Hot Stocks
Co-Diagnostics awarded UK patent for RapidProbe probe technology »

Co-Diagnostics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$47.46

0.03 (0.06%)

06:31
12/14/18
12/14
06:31
12/14/18
06:31
Downgrade
Cisco rating change  »

Nomura downgrades Cisco…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 10

    Jan

  • 04

    Mar

DB

Deutsche Bank

$8.87

-0.16 (-1.77%)

06:31
12/14/18
12/14
06:31
12/14/18
06:31
Periodicals
U.S. lawmakers call for additional 'scrutiny' of Deutsche Bank, WSJ says »

U.S. officials on Capitol…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GWR

Genesee & Wyoming

$77.80

-3.01 (-3.72%)

06:31
12/14/18
12/14
06:31
12/14/18
06:31
Hot Stocks
Genesee & Wyoming reports November traffic of 259,000 carloads, down 4.4% y/y »

Genesee & Wyoming…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIS

General Mills

$38.12

-0.44 (-1.14%)

06:29
12/14/18
12/14
06:29
12/14/18
06:29
Recommendations
General Mills analyst commentary  »

General Mills price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.